NHS has 'missed the boat' for ARB switching

摘要

SWITCHING patients to generic losartan does not represent good value for money for the NHS, a leading cardiology pharmacist has warned. Speaking at an educational meeting, held by iRx Solutions in London earlier this month, Helen Williams told participants that for patients taking branded angiotensin-II receptor blockers (APvBs), the costs associated with switching them to the generic product could not always be justified because many of the branded ARBs are due to come off patent soon.